超声肝肾指数诊断2型糖尿病患者脂肪肝的前瞻性验证研究
这项两中心前瞻性研究以MRI质子密度脂肪分数(MRI-PDFF)为参考,在训练队列129例和验证队列263例2型糖尿病合并代谢功能障碍相关脂肪性肝病(MASLD)患者中评估超声肝肾指数(US-HRI)的诊断性能。US-HRI诊断≥S1的阈值为1.16,敏感度82.7%、特异度80.0%、AUC 0.81;诊断≥S2的阈值为1.47,敏感度49.0%、特异度73.0%、AUC 0.61。结论认为US-HRI对诊断脂肪肝可靠,但评估更严重级别脂肪肝的性能不足。
要点
- US-HRI诊断≥S1的阈值为1.16,敏感度82.7%、特异度80.0%、AUC 0.81。
- US-HRI诊断≥S2的阈值为1.47,敏感度49.0%、特异度73.0%、AUC 0.61。
- US-HRI区分S0与S1-S3的成对准确度良好(0.78-0.89),但区分更高级别时下降(0.54-0.62)。
核心结论
- US-HRI是诊断2型糖尿病合并MASLD患者脂肪肝的可靠工具,但评估更严重级别脂肪肝的性能不足。
研究设计与样本
- 两中心前瞻性研究,训练队列129例、验证队列263例,纳入时间为2019年至2022年,以MRI-PDFF为参考标准。
诊断标准与关键数值
- 脂肪肝按MRI-PDFF分级:S0(≤6.5%)、S1(6.5-16.5%)、S2(16.5-22%)、S3(>22%)。
- US-HRI诊断≥S1的阈值为1.16,敏感度82.7%(95%CI:77.4-87.3),特异度80.0%(95%CI:56.3-94.3),AUC 0.81(95%CI:0.76-0.86)。
- US-HRI诊断≥S2的阈值为1.47,敏感度49.0%(95%CI:39.1-59.0),特异度73.0%(95%CI:65.3-79.7),AUC 0.61(95%CI:0.55-0.67)。
- Obuchowski测量(四分类问题S0至S3)为0.79±0.01;S0与S1、S2或S3的成对准确度为0.78至0.89,区分更高级别时降至0.54至0.62。
临床应用与阅片要点
- US-HRI可为MASLD合并2型糖尿病患者提供检测脂肪肝的定量方法,但在更高级别脂肪肝分级方面效果有限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the performance of the ultrasound hepatorenal index (US-HRI) for the diagnosis of hepatic steatosis in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD), using MRI proton density fat fraction (MRI-PDFF) as reference.
MATERIALS AND METHODS: This two-center prospective study included 129 and 263 patients in the training and validation cohorts, respectively, between 2019 and 2022. Hepatic steatosis was classified according to MRI-PDFF as S0 (≤ 6.5%), S1 (6.5-16.5%), S2 (16.5-22%), and S3 (> 22%). Obuchowski measurement (OB) was performed to assess the diagnostic performance of US-HRI in the whole cohort. Optimal cut-offs of US-HRI for diagnosing ≥ S1 and ≥ S2 were identified in the training cohort by maximizing the Youden index and were applied in the validation cohort.
RESULTS: Overall, 392 patients were included (mean age, 59 years ± 9.5; 235 men). The OB (four class problem S0 to S3) was 0.79 ± 0.01. Pairwise accuracy was good for S0 vs S1, S2 or S3 (0.78 to 0.89) but decreased for distinguishing among higher grades (0.54 to 0.62). Optimal US-HRI threshold for diagnosing ≥ S1 was 1.16, with a sensitivity of 82.7% (95% CI: 77.4-87.3), specificity of 80.0% (95% CI: 56.3-94.3), and AUC of 0.81 (95% CI: 0.76-0.86). The threshold for diagnosing ≥ S2 was 1.47, with a sensitivity of 49.0% (95% CI: 39.1-59.0), specificity of 73.0% (95% CI: 65.3-79.7), and AUC of 0.61 (95% CI: 0.55-0.67).
CONCLUSION: US-HRI was a reliable tool for diagnosing steatosis in type 2 diabetic patients with MASLD. However, its performance in assessing more severe grades of steatosis was inadequate.
KEY POINTS: Question Ultrasound hepatorenal index (US-HRI) performance for the diagnosis of steatosis in type 2 diabetic patients with metabolic dysfunction-associated steatotic liver disease (MASLD) is not well defined. Findings US-HRI demonstrated good diagnostic performance for steatosis (S0 vs S1-S3), but this decreased for diagnosing S2-S3. Clinical relevance US-HRI provides a quantitative approach for detecting hepatic steatosis in patients with MASLD and type 2 diabetes, but has shown limited effectiveness in grading higher grades.
引用
- Hamadouche M, Vilgrain V, Hobeika C, et al. Ultrasound hepatorenal index for the diagnosis of steatosis in patients with type 2 diabetes: a prospective validation study. Eur Radiol. 2025. PMID: 40560415. doi:10.1007/s00330-025-11774-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。